Combination of Renal Angioplasty and Angiotensin-converting-enzyme Inhibitor Can Reduce Proteinuria in Patients with Bilateral Renal Artery Disease

Intern Med. 2019 Jul 1;58(13):1917-1922. doi: 10.2169/internalmedicine.2076-18. Epub 2019 Feb 25.

Abstract

Recent large clinical trials failed to show clear benefits of percutaneous transluminal renal angioplasty (PTRA) as compared with medical therapy on patients with renal artery stenosis. It was also reported that proteinuria is an adverse prognostic factor after PTRA, and PTRA is less effective in patients with overt proteinuria. From the renoprotective point of view, to reduce proteinuria after PTRA is an important therapeutic goal in patients with renal artery stenosis with overt proteinuria. We hereby describe two patients successfully treated by combination therapy with PTRA and administration of angiotensin-converting enzyme (ACE) inhibitor for bilateral renal artery disease with overt proteinuria.

Keywords: angioplasty; angiotensin-converting-enzyme inhibitor; proteinuria; renal artery disease.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angioplasty / adverse effects*
  • Angioplasty / methods*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
  • Humans
  • Male
  • Proteinuria / drug therapy*
  • Proteinuria / etiology*
  • Renal Artery Obstruction / drug therapy*
  • Renal Artery Obstruction / surgery*
  • Treatment Outcome

Substances

  • Angiotensin-Converting Enzyme Inhibitors